Fenfluramine hydrochloride

Fenfluramine hydrochloride is a serotonin releasing agent that was previously marketed as an anorectic (appetite suppressant) but was withdrawn from the market due to its association with potentially fatal cardiovascular side effects.

History[edit | edit source]

Fenfluramine was first synthesized in the 1960s and was marketed for the treatment of obesity under the brand name Pondimin. However, it was withdrawn from the market in 1997 after reports of heart valve disease and pulmonary hypertension, a rare, but often fatal lung disorder.

Pharmacology[edit | edit source]

Fenfluramine acts primarily as a serotonin releasing agent. It increases the level of serotonin, a neurotransmitter that regulates mood, appetite, and other functions, in the brain. This leads to reduced appetite and helps in weight loss.

Side Effects[edit | edit source]

The use of fenfluramine has been associated with serious side effects, including pulmonary hypertension and heart valve disease. Other side effects may include dizziness, dry mouth, upset stomach, and sleep problems.

Fen-Phen[edit | edit source]

Fenfluramine was often used in combination with phentermine, a practice known as fen-phen. This combination was thought to be an effective weight loss strategy, but it was found to be associated with an increased risk of heart valve disease.

Current Use[edit | edit source]

Despite its withdrawal from the market, fenfluramine is currently being investigated for potential use in the treatment of several neurological conditions, including Dravet syndrome, a severe form of epilepsy.